Other
Gnrh Antagonist
0
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
GnRH Antagonist is an early-stage landscape with 0 programs across 1 company. The most active players are Ferring.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
27
clinical trials
Completed18 · 67%
Unknown status5 · 19%
Terminated2 · 7%
Recruiting1 · 4%
Not yet recruiting1 · 4%
Clinical Trials
Trial Activity
27 trials
Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET
Completed·—·Phase 2·NCT01219153·136 enrolled
Severe LH Suppressed Patients After Administration of a GnRH Antagonist
Completed·—·Phase 4·NCT01936077·50 enrolled
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
Completed·—·Phase 4·NCT04724486·50 enrolled
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.
Completed·—·Phase 4·NCT04724343·50 enrolled
Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders
Completed·—·Phase 3·NCT04537078·90 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)